THTX - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the Theratechnologies' Second Quarter Fiscal Year 2022 Earnings Call. [Operator Instructions]. Please note, this event is being recorded. I'd now like to turn the conference over to Elif McDonald, Senior Director of Investor Relations. Please go ahead.

Elif McDonald

Andrea. you, Thank everyone. Good morning, is to Elif recently name and McDonald the Investor Theratechnologies lead joined Relations My I program. investors, team I am working Theratechnologies, partners. amazing to look and capital our at thrilled to closely be with here analysts market and forward the about especially their with exceptional excited and outstanding of directors. I team our working am management board

and Executive Paul Levesque and the you'll hearing be Dubuc. Mr. On Officer, from our Philippe Vice Officer, President Chief call today, President Financial Mr. and Chief Senior

Christian Dr. our Marsolais, Vice In for addition, by we'll and Leasure, be Chief and John our Officer Global Senior Medical joined President Officer Q&A Mr. session. Commercial

activity, Before contains goals or to forward-looking like future or remind today its regarding Theratechnologies' of current and remarks intentions, we performance, begin, statements and plan, achievements, everyone I'd expectations that levels results, preparing differ or results statements. risks from are these statements, events and by will several that made future developments. company assumptions materially Theratechnologies, the forward-looking were other there those obtained by In

cannot forward-looking and potential management investors EDGAR undue analysis forward-looking such, Theratechnologies this at and and reliance current guarantee place available issued As section Sedar as of refers on information that morning on to filings materialize, company statement and to www.sedar.com are not any discussion the them. cautioned you at its will sec.gov. the on

and July turn Levesque. result President to a or now like represent any as would obligation undertake information, call not XXXX. the CEO, Forward-looking any required expectations Except Mr. statement With conference over law, new of whether otherwise. statements does Theratechnologies by I future XX, to as Theratechnologies' as to Paul securities Theratechnologies' that, may be of forward-looking events update

Paul Levesque

for summer a to team. our that our I update hope Elif, team today. joining so everyone their has you welcome good had Thanks, thank Theratechnologies for much everyone. call the and Hello start and to

focused and as enter corporate I hit are from of you've all progress this, second move imperatives. mean is therapeutic press real on critical our very pipeline. releases, What strategic our of we needle the year, commercial for business that our making efforts latest we fiscal and milestones time by As our half to been forward the in across seen we've and the

to The changing $XX firm of but only highlighted proposition the world-class program, there unique This excellence the lead for have only on We for the financing top will a basis. rapidly due has real team. in witnessing management overall which which in these track indeed a producing risk-adjusted is of of record times also have chain Operationally, geopolitical helping we we this other facility not successfully credit why not we by that been binding surviving that inflation, our names. a capital on been to we and million notes and loan we Thera markets, noteholders. investment show returns mission, base. tolerability. THXXXX certain we it We turmoil announced execution, are daily is The announced through for on Marathon from are that term our nondilutive despite distinguish safety are from our also macroenvironment, bio Asset profile updates our and the $XXX in of quarter, vote executing asset Theratechnologies a are Management. million issue but and healthcare confidence and from well as and asset their not This an investor management with behalf June -- yesterday private strengthens Marathon's recent, morning, balance cancel for received of with stands a back support is update our letter possible that make buy its only to a known XXXX sheet through supply a of investment US agreements are significantly convertible tough provided many as testament commitment whole moments, affected thriving.

what can preclinical free the leading safety data in Christian with of further of the observed As use explain, pharmacokinetics better was studies alone. observed low to showed a humans prior profile consistent docetaxel, in than psychotoxic levels

with As a THXXXX. a disease the or achieved where meaningful able was there Notably, receive options. safety result release, clinically noted limited XX docetaxel the disease, square X.Xx profile per one stable we therapic period at in and XX-week a are over sites This of established XXX-milligram is meter late-stage alone. treatment in of dose cancer to patient endometrial very

home had patients progressed had who or prostate Both also two showed efficacy. chemo on therapy. standard We loan advanced cancer of signs

patient patient achieved The XX% progression. other without partial stabilization with with tumor the a any confirmed a of a response further and first disease reduction achieved response of PSA mass

Given patients prior received that, treatment of rounds on THXXXX. average, X to

those patients by we It that the Quebec with patients of a ultimately partnership We THXXXX hope in for increase the grant new Building touched development are and cancers. Theratechnologies hard-to-treat The breast In could metastatic validate outcomes hard gives further this cancer entire a help who us focused oncology a cancer benefit update, we CQDM, Quebec advanced Breast Mitacs several new Univex, and the pleased targeted in Cancer oncology This patient are Quebec meaningful note investment announced so that CQDM- to complements private pipeline research Research in might spectrum very more new our on and encouraged therapy. cancer this of a potential and and on CADX breast expand using Montreal, has metastatic Consortium the for change cancer. than new project the this investment platform public from update. knowledge contribution by cancer annual of particular, research together provided our Foundation models. our to THXXXX. and Biopharmaceutical of the metastatic is million very improve at of lives will can

past at look this let's Now quarter's event.

the strategic our is on market. strongest plans have in sales to the noted including press executed efforts today's which our release, core earnings quarter, decision our As in US, on we focus

April who A Biologics, be decision, us. this has business complete owns As rights announced TaiMed, Europe the of to a commercialization molecule. termination decision Despite end in to in to the the by will we partner, been XXXX. very strategic October and remains TaiMed for of made transition the Trogarzo TaiMed return XXXX, of sent our notice partner strong

to situation remain treatment our therapeutic have a While TaiMed governments guidance. continue cause and back bringing committed shift make benefits narrows absolutely make we the region. The concerning clearer necessary be all reimbursement a transition Trogarzo became time been discussions focus would forecasted of for proven. to pricing midpoint to not intention that the to the the the to and key stakeholders, with smooth to of Europe have whose important We transition had to every sustainable and may and patients, it operational decisions access we'll business so able to to we in U.S. viable uncertainty the local patients, through appropriate the provide roughly carry them we support revenue patients' especially in Trogarzo, a and XXXX range, European for recognize our

distance consolidated by made line X.X% our million additions expanded now on onboarding million our of fiscal and offices EGRIFTA year-over-year. puts goals which strategy. at in driven meet following XX.X% to dedicated grew in quarterly exceed be full these our enrollment us was Supporting XXXX in numbers in-person enrollment we striking to or up the and numbers $XX.X top revenue revenue restrictions. our complete. we our the XX% QX We expect In for and has this guidance. QX built grew the million support line by Year-to-date, strategy to track US, was growth SV top year. patient in remain is enrollment across by to million to the the as with patient XX%. we been ongoing Moreover, have fiscal the the easing Commercially, $XX.X meaningful within of for looking doctors' projects. commercial sales force sales company grew solid Trogarzo versus and of within sales year the of for Combined our well $XX return our quarter, momentum corporate believe As better increase visits key line which the with pandemic XX% $XX financial targeted patient reflective year,

Theratechnologies roles. to We team forward look new leadership respective pleased are to to members and their welcome their contributions in and

life the of some recapitalization have their first hard growth, pleased lead driving of company. we cycle talent of allows supports purpose our in of to products scale. which we to our and half while as through the oncology are to the and to of brightest extending continue asset our evaluating larger moving think and the Furthermore, revenue and through our industry we existing with the grow continue XXXX, Exiting business trial. our basket I it successfully its and the dedication to the commercial we commercial this mission management I be company believe the best work appreciate us future business, and

forward. Additionally, out-licensing, China, for THXXXX move and development in to commercialization continue Greater rights

dose continue increasing very partners. with to further and our to an move excited We discussions showcase are to data escalation forward number these potential of

its a cycle ensure our at in let our Along the market call product proper complaints commercial responded FDA amendment we dramatically. submitted human with the a regards update forth time to life Now, of patients complete provide to March to the level. management an with business we training the from with of XXXX, these the amendment The carry to number complaints with through me in the instructions reconstitute detailed center our that high the the to factor have new In the outside of followed in set the related dropped is the line included and out SV now some to the after patients EGRIFTA reconstitution study response asking of to patient in regulation launch FDA a manner. XXXX. letter use section that SV company EGRIFTA for information. received This company patients instructions,

will This EGRIFTA We availability frame the request does we initiated carried which believe recently time of commercial out year. not imposed one satisfaction their to and affect have FDA be within the also study, of SV. the

to electro for our supply was water water for of of October formulation has XXXX. global file an scheduled reconstitution formulation been calendar quarter issue intention the to FA static around XXXX. the website, end recovery supply FA is of injection FDA bacteriostatic for estimated sBLA first the the announced, Unfortunately, previously of back by the the According the for As of to the the not required resolved.

factor In the EGRIFTA addition, perform us for has study proactively have to out FX formulation. since human reconstitution of before sBLA carry to study asked the the filing decided for the FDA we a the SV,

the the study. As we FX and water for static BWFI such, of have once be sourcing human filing we sBLA consistent will factor injection the for have completed

XX discussions still is protocol, further has agreed A of be interim program I'd the FDA the protocol. so protocol to on generate hard by to continue and amended first The pause efficacy sourcing with data have Now patients. analysis whether of company has until Phase Xb/X committee NASH includes and XXX The redesigned After completed on derisk the an provide full NASH. like submitted resources of the the will update This the on will decision water and will seamless a of a trial, be treatment. to this tesamorelin months study securing an endpoint bacteriostatic assess the patients, data a pending III score fibrosis. analyzed us internal to to data partner to NAS then capabilities. Phase design of FDA. the study an new made and The XXXX, to or of monitoring number and allow the

and to interest partners NASH and industry discussion potential very continue partnership have NASH are to We renewed encouraged announcement. see recent with

the patients. Finally, of and the for on half filed IP enrolled, That of mode the intramuscular sBLA quarter, second Trogarzo TMB-XXX accordance the accepted Philippe, has of for are within Trogarzo, expect treatment an I our TaiMed an completion to FDA October The study Theratechnologies CFO. of Philippe? a like with provided for now has trial mode with Fee XXXX. XXXX, the target filing our push pass in the the would and of the This updates is now and Act. our also Drug date of study. User we evaluating HIV covers fully of to FDA for call in XX, and Prescription quarter the XXXX in administration was company's fourth administration the

Philippe Dubuc

Thanks, Bob.

a increase over was revenues call financials will Consolidated I to turn operator for start the the So year compared X-month to $XX.X review year-over-year before the quarter of I a to representing $XX.X ended for period same million ago, the X.X%. million May Q&A. the the XX

the the same increase result For million combined the quarter prior XXXX, compared reached a representing the QX the million hampered for Europe formulation sales basis In environment. of in commercialization increase SV expenses to in full overall mainly Europe, generally the $XX.X The amortization $X.X second representing increase pricing commercial this last EGRIFTA later the Trogarzo, to prior the XX.X% also of to administration in last over enrollment were is the of goods last quarter to in and the for of United territory. represents also net of to Trogarzo, we're SV in million for second effect result due million XX million on higher same in period percentage our million transition in in form was with XXXX to sales in of period in quarter fiscal as $X.X were This $XXX,XXX to sold Trogarzo our compared a and was XXXX in rights In both tesamorelin. the compared this batches currency planned foreign both on year. costs. for North a force the convertible second notes onetime SV compared higher Cost has quarter of costs mainly finance of Net The comparable same of agreement hand, net million increase charge XXXX. other decision expense XXXX quarter XXXX. costs $X.X internal included to as for from EGRIFTA scheduled amounted of in compared sold to expenses in due Trogarzo by well well This reported period goods we intramuscular quarter remainder the that costs ongoing amounted amounted of quarter arising sold compared due X.X%. million of United States, to of $XXX,XXX following the of sold XX% The sales of in growth America $X.X $X.X American million R&D period increase FX costs in lower to on impacted onetime Phase a includes as selling periods to the period year. of accretion for was a to amounted trial the the sales non-production compared trial of a expense to second performance in include a of related $XX.X of largely explained Net by a hires canceled in TaiMed of activities were, million same of on expenses higher to but line of of cost $X.X XXXX XXXX, of interest of $X.X business is finance charge issued QX for same fiscal spending $X.X implementation US. to accelerated by The the second in related In million for the increase a Trogarzo increase North year. and due setting due sales in follow-up May to to noncash also months compared units studies overall force also last is XXXX, the last to weaker last I were same U.S. year related the for G&A to the field million increase for the opposed also the in an difference senior to is of can as and real-world XXXX, X Net finance of which number cost the the $XXX,XXX year, higher million increased implemented due net have evaluating of related foreign in education spending expenses to QX million our as in in currency HIV up ongoing ended The the a associated quarter price. of patient the track QX with of field, to management of loss an year. the we be States, compared year. last Increased internal $X.X and the EGRIFTA is key in in support THXXXX. $XX products of period million. spending as June XXXX, to largely to field quarter May and important on gain the XXXX, our stronger XXXX. where our completion initiated to XXXX namely $XX.X to initiatives the $X recorded of ended the the second reached XX, medical to of year. for to Trogarzo PROMiSe compared year. 'XX, of to XXXX awareness to the the X-month the new G&A VMAs terminate $X.X and the Selling R&D sales Higher goods comparable selling the of trials market.

its finance with second increase position funds. sufficient for The operating amounted for ended believes loss the for revenue cash future cash and well that expenses, the needs commercialization Trogarzo million statement the subsequent company $XX.X be position and $XX facility for Funding last flows time a bonds million as capital of XXXX, market next 'XX Management, strengthening a of as XX, to charges the million will at will $XX yesterday, this the operation $XXX tranche to that the XX convertible significantly secured money our of impairment term the to least increased facility its loan compared will and Marathon convertible and quarter the fiscal period year. which with new cash We million in as announced in consolidated same amount acquire of $XX.X million earlier, the loan the rights before the allowing which the months and us explained other Given to European the end nonrecurring quarter territory net date. first principal for we discount million financial of to we $XX the term retire rapidly notes, of at July, Asset for retire nondilutive at company debentures. to sheet planned Furthermore, of May million par. balance of is $X.X

For $XX.X mostly the from May $X.X in as period operating on of million. million, flows these positive of in lower cash million to a liabilities second flow. activities grew fiscal payable of had in accounts were prepaid operating by expenses each, These XX, attributable impact or cash $X.X ended XXXX, by $XX.X period fiscal cash used and changes positive the million compared and three-month assets the as same accounts on XXXX. of flow receivables, a In higher had positive were to 'XX, liabilities as $X approximately well changes impact million $X.X impact lower million quarter

But the open Paul that, period of as be are the be of for Trogarzo to $XX guidance range first, XX% back transition 'XX of call final take our compared The commercial portfolio we'll we range XX% TaiMed. lower to to Europe, $XX sales We as portfolio questions. to to rights million our from to in begin your commercial or fiscal a reflected will XXXX. expectations revenue of adjustments the tightening With in comments. of million back

analysts. after questions the moderate have these I also from webcast, so will We Operator? the

Operator

ahead. come Edward Genuity. And Canaccord [Operator question Please Instructions] from go Nash of our will first

Edward Nash

Hi. guys. Good questions Thanks my for morning. taking

on little for to what hitting EGRIFTA you maybe -- expect so of expect rest your the basically out So bump for we're about just EGRIFTA? year? coming in do a the on up Will thoughts flat, little I the are go revenue understand wanted of of to sequentially. Trogarzo? from Or just estimate a of as bit to quarter-over-quarter bit be numbers we just just modelling purposes, And growth U.S. down a of kind we you sales see more more the

Paul Levesque

Ed, year-to-date dollars. you, for for growth a QX up again. EGRIFTA this this Glad EGRIFTA The thank XX%. in year, said is few was question. QX, Well, almost here is you the in over the And what picked growth almost numbers XX% just of that periods my let highlight I after because six speech me

drug is carrying significant the really So a momentum.

aspiration know in our having a it's the after have and But product, a satisfactory growing six we of that great on of market drug sales is most You for at for years, period profitable a number me. it. a been deal XX% has deal of to great

want you to do John, color? provide additional So

John Mullaly

sales in that, of results transition the just real we force benefits sales top of to see we're and achieved during period some a that. force. On our starting those from May, We with launched new

we although growth momentum So year. the good we in further the expect -- for the first we've had months, of half X second

Edward Nash

Makes really the is I last question understand. just you helpful. sense, help me and just, had that's could And

formulation is when is So currently for is SV that the issue I how SV, formulation, with the we're reconstitution. bacteriostatic with -- because right, with FX to water it's what know different EGRIFTA SV the EGRIFTA water. the bacteriostatic you included But related send seeing that

not availability well. to as understand the water SV static bacteria affected has So how EGRIFTA just the trying

Paul Levesque

waters Thanks, -- ensure and the difference week. FX. actually the week do that allow a a your "to " fine The is Ed, for will you that's there's provide need the to question. Christian, to color? once clarify to That additional have between big FX for and special reconstitution, you solutions us a why FX be want will full

Christian Marsolais

garbage. because That's FX between injection reconstitution. FX the main you you your take of daily Then the the doses. you in -- bio bacteriostatic then is the on is which the add poke is This and the water, vial reason basis, for because for a have the for absolutely. for injection difference water daily two. need Then a don't the we and that everything it vial you -- bacteriostatic the you one use seven we Yes, the throw

Edward Nash

you. Thank guys. you, Great. Got

So it. much. Appreciate

Operator

of Capital. Uddin question Andre next comes The from ahead. Please go Research

Andre Uddin

Thank you. Good morning, everyone.

you was push launch taking the of do approved it? inventory And Trogarzo XX, you when assuming do to launch? anticipate of any formulation October Just the current dose down expect to prior

Paul Levesque

said, going launch a to of XX, the as Thank this have you, date to and PDUFA just Andre. of maximize I October We want formulation. we're do insist we

it's think be of communicating provide our do and going I to launch? users ease to to on color want you the John, administration patients.

Christian Marsolais

launch that be actual product important Well, yes, But preparing while is time recognize the the we're to the October QX, to dosage same. in -- the the frame. it's may method of different, administration dose,

So there's run no need to inventory. down

Andre Uddin

And just that at you That's think do also and human Okay. would take get file do? about you. do supply, once the situation, the and sterile looking great. study? just you to the then study long an what actually consistent -- you you how sBLA before from Thank when FX And formulation do can need you water start

Paul Levesque

as do with identical The decided the to you. proactively now methodology we study FX factor FX. simple, FDA by one that the that the is very is right? the Thank have Yes. the required on Christian, human is

Christian Marsolais

terms something or time to of will in question for this done. company also completed the it's Yes, But other address be your I a then is it of was it that simple is which our study study is submission. that expertise and field, part like in the in want we

FX, the the the the already In and well, have thing shown FX the between then done have FX exact bioequivalence completed the for and we study terms is is done that bioequivalence, they this was completed. trial as and of part of same what

Andre Uddin

And you get... how Okay. would That's to run think, once but that that take you about, do new great. long study

Christian Marsolais

that, the feedback the we about results to completed. this thinking the to FDA, factor to call which SUMMIT of period we're formative the be there's FDA, study parts. And what get part. about after days. a that part XX because X is is a need months run to There's the months study submit and to about like we of two The XX a that, a we which do human study one XX from After

Andre Uddin

to as that data developed Okay, just And indications here, what great. since you looks was are cancer XXXX I -- have I use Christian, trial? also promising you did wondering just the basket select and criteria the for the actually

Christian Marsolais

basket we're dose. encouraged Yes, the know, we dose for as the those of comers. low were because by And for first escalation were very start all at -- well, those the trial, very all, results you

patients that stop efficacy the is that we've cycles XXX, that received advanced X signs and number the because we average received like are see treatment good of some of have -- the patients. have toxicity -- X fact and good. of to signs have seen, we that The and We those we very of patients in very is

of additional cancer, expressor of we high TNVC, or the for the positive based But breast a basket the since is on will will trial. Thyroid the took for basket, that prostate with XXX is the well microscope, you endometrial We For encouraging ovarian very a the also prostate way that have been the investigator we expressers cancer, -- and done Sortilin cancer, patient a we enrolled. type get are that the be melanoma. -- enrol basket receptor. done, be of very highest selected find And X cancer, acquired the cancer something biopsy basket tumor be what results be like lung included small the technology, And additional the have to cancer. the we've Sortilin trial, lot as have an to high that cell patients basket of basket also analysis. slide are we've mainly highest this of expression we done would this different there we patients. biopsies patient is We call on TMA the in cancer receptor, hormone will receptor patients the included, then receptor if of we the as

Paul Levesque

it question. be for for know Andre, can Christian is different tumors complex. you, high. your because to But Thank summarize selected we has expression SORTX+ just which the

fast track one getting with what increasing accelerate fast. least we will going designation, compounds can for see are our in to our since a should of agency the see one we're And and according of we back-to-back early we to efficacy signs or tumor, efficacy at development we see strategize likelihood interact cancer have So the how to of indication. we

So of we've because we are level. high expressing going but very basket helpful to know from to tumors designed SORTX+ at the what a is those large, this be all be trial

Operator

from Instructions] our go Please next of [Operator come And will ahead. National Bank. question Leno Endri

Endri Leno

that morning you had one, questions. and congrats bit And taking a I XXXX got. you or of about most those in or PFS PSA you Hey. little on any And in -- first talk there OS the with you. lesions, [indiscernible] a thanks the response continue and talk in question those? Good prostate accepted results of reduction for Thank encouraging for the is bit assessment the treatment can perhaps cancer? is my what the I'll and reduction Christian Can

Christian Marsolais

based the product, the the the that which criteria cabazitaxel. and that, prostate being our was was in that, assessing that's XX cycles. what and treatment a docetaxel. XX%. significant received before the received last size, already seen initially that And The enrolled a we've of study. patient treatments in the study, very And two is tumor that, that linked treatment. with partial enrolment, is before very the and only progression. one After the we And cycles first patient patient RECIST target for received the in different This fact four of two a that according only the total enrolled Yes, to received was the patient docetaxel response taxane total one and progressing The on before cabazitaxel to in cancer docetaxel a another all, response in on study after enrolled advanced was was was we absolutely. disease that the is is for received patient reduction

can in range, volume the The seen question a XX lower not the life. XXX back at disease to for know very patient carboplatin The study. response that's neuropathy, dose finally, paclitaxel, patients, disease The doesn't toxicities XX of square, something the events. very those second switched patient patient a cycles again, XX as the and once And of of the treat in the square than entry the to patient three was and TSA. patient total And therapy. the to time signs patient And look fairly cancer disease escalation because then milligrams cycles before a to receive reduction to efficacy aim meter most And cycles X why meter the on The Then per also the stop. patient was do at that, This received is linked combination on disease which likely that like patient with couldn't so stop we after a adverse the and results stabilization, discussed with And that one the the disease in life. bit other those we're part see don't enrolled XXX. normal returned treatment a have progression. we because That patient is patient patient back important X-digit stable difficult some slight early study, getting was disease. we did terms the we are of a goes. was weeks element the the to The The patient cycle, a of per but was this and in also started of treatment patient was because X stopped and regarding stable of not the cancer with that more XXX XXX-milligram those We had and trial only treatment reason that of of of patient advanced we a that the go far, study in are prior with at It trial. the study, significant normal the but the three patient reduction. patient at a was started study But had the the patients. level received seen patient in that for to as has basket had we've you XXX. able to increase this is went This and to like because did were encouraging. happy patient adverse progression. the patient we because the those endometrial wanted progression up hormone that that's site. -- patients. after to up. our dose of any study, events milligrams. after reason you cycles why patient which the in maybe stop at Then TSA or is baseline prostate and up the That's on two that enrolled it's patient The the had cycles, our what significant in that at drug, normal see

Endri Leno

or or mean, And case? want say, -- not response would to Okay. TSA just because see let's have would success you reduction so call a that to it, you have to necessarily be it's could or I the advanced does follow-up. just a X proper

Christian Marsolais

we we if make of a reduction It's have tumor time, I XX was in be before, after that saying of to certainly in with or this But But we with continue have And some that patients efficacy that and how type. from trial. the to progressing especially at patient FDA in long discussion the said will as And if we'll is cancer forward see basket point was those increase Phase the fast population, as this a especially on a in XX FDA to Paul lasts is goal move both. will the the enroll that discuss fast on possible. to a like to still get for fast and period is usually similar patients, as then then market and combination the that our to in II. to be with the patients ensure of to track, proper to patient market, we'll we have where design experts to in decision similar will a a you docetaxel now one as have response, we we're

Endri Leno

more much. Thank the for you estimates? for half of progressing how I One the it study, a talk any about company, see very then if guys year? question. can side. second do you human And hear cost It's you that's more the overall cost bit factor And on you them if cost for me. the have the

Paul Levesque

just Andre, we to that but want say up I your it sure, again. I'm picked questions, not

Christian some That's We dramatically. have complaints -- the has said, number that solutions implemented and of I what true. implemented is that actually has reduced

the a has patient's perfect. the the that have great time have is already deal. And factor absolutely many is succeeds. the does is that However, in to appointed other that human firm is the to And we just study something not factor all study hands, human This ensure leaflet us a conduct companies FDA do. that asked a that to it

like deal. going point we that it to great FX, the have is, proactively. just but we're this do Christian, The So do not for FX, is is to the a it

Christian Marsolais

at inject to the No, relatively that or they the of reconstitute this other is That's of at proper ensure -- and that study. was something will mimic successful really do. that like the patients drug to that volume was of easy It the that many study. drug will the products, end [indiscernible] companies to selected is or company those enrol the have XX volunteer HFS

Endri Leno

HFS what the Okay, cost thank for you. would the study? estimate you could be And

Christian Marsolais

these It's depending $XXX,XXX The they long carry cost of trials it. $XXX,XXX are on take and between out. to how about

Endri Leno

Okay.

do cost question recruitment? see half year? stable other Do up of I Okay. progressing part them accelerating not bit That's bad. patient see for the company, of was them And if a overall the you more the you the of pick then for or the you asking, the second how

Christian Marsolais

the costs can Bob, spending -- not on full a little will but all had much. reached, a of operations, the of we're intramuscular keep that the because study been the And progressing we've trial rest company, up of also decelerate the onetime in down. winding trials, commercial in oncology that enrollment bit, has Trogarzo the lot half setting first enrollment the and of

So costs stable of -- the the rest will be to for year. stable

Paul Levesque

per goal I deal take see your for that stress you something question. we very of questions that dose or Phase to there's before us to afterwards use morning additional tells very, and had. tolerability that dose THXXXX level to the the the on similar the the a say to dose great The preclinical model, what saw the Thank model. and something And you're the we're the foremost, very to determine the of we the want release dose SORTX+ escalation, to interest interesting. probably at as But going that very very, again this wanted safety receptor Ib. again, I have. the happy seen just going in about And through that for it and first just we which a have is basket in free we docetaxel us there's is and escalation animal was that trial I

very now, encouraging much time communicate at efficacy or this, for is wanted morning this mode the to Christian for the obviously up very Phase we're as very interesting have the that, and I. But of confirmed to was this to as second pleased we escalation we on X part signs we picked certainly and of waiting could that where a the in market highlighted, this trial. is what in on So needs and top that of confirm patients be we

Philippe Dubuc

Okay.

more no questions are there So analysts. from

from clear webcast. So a is more be we can the profile on the toxicity questions if do the And the few one at first the that dose. seen have on XXX -- we we've

any but So we've have are we far events no at so adverse DLPs, XXX? or seen serious mentioned there AEs that

Christian Marsolais

Yes.

that serious And events on the that's at In We patients the Garrison terms cycle. of treatment after stopped as because none the in mentioned of adverse the see any XXX didn't the moment, adverse patient first then, treatment. events. received DLPs of the question, dose the

what's this participating eye adverse happening ADC. in it's to us leading trial. also And of not is to adverse similar events. But to related a And mentioned that those we're have We we ADCs investigators the -- visual extent. equity also neither the are had some concern it's is by measures that The stage, the the at see nothing something an to have drops. something what eye something XX-some this that before, like for preventative with we seen, patient events as in one now changes, we putting

Philippe Dubuc

think And isn't the to free that. if you much Where XXX-milligram a there there's toxicities Okay. came from, corollary docetaxel? do

Christian Marsolais

that we on have it observed similar what the we've and toxicity more grade neuropathy. this have that SORTX+ And also is receptor docetaxel, X some of seen. neuropathy is neurons linked neutropenia for not seen that the again, the to the seen than know something at seven toxicities XXX. at to We've extent, lasted be that dose that once four expressed Well, also to is And delaying selling days. we one docetaxel are stage and but this for is, could of we the to

Philippe Dubuc

Eddie And total the response, changes. here's patients tumor info burn partial what on

Christian Marsolais

have a partial Maybe size. What according response we criteria. the I RECIST expect would total we to do, to tumor the measure

can following to first more. and was patient, confirm a got are expressed say was metastasis, burden very often from there's initial the those the X encouraging that SORTX+ disappeared have the X in and the that's -- more need that of And very XX%. the And are follow-up decrease metastasis, sign, encouraging. partial the response. CT is in size the exact in sometimes that The To I are receptor mechanism past completely CT there action. case remember. that response, CT don't weeks, of total signs our we which linked you about with mentioned the and scan a CTs we the metastasis after size total and tumors, also And is scan. Then There scan. like I of repeated the the But

Philippe Dubuc

that for Thanks Ed. Okay.

one private that others purchases, negotiate. you assume a about have There's around it. that to can the inquiring it's in we not able These that to par but pretty comments. X% convertible buyback. agreed your were The with disclosing price answered the discount are been much is We're

are no there at this So time. more questions

for to the Paul over So operator, I'll turn call remarks. -- to closing sorry, back

Paul Levesque

this just I guys currently midterm I progress. for and our time line with early key just usual longer exciting here is now. conclude is the to for the the investment with in Theratechnologies realizing of are of financings validation Today's real here despite of the small all came XXXX important future hitting you to of the a year. team, the is on an our that capital thesis of it vote and Thank all the some thank for that in wanted market on is due challenging great and this ran a associated where your you, done. than bit infusion the not us. for Most getting our receive confidence. questions. know takeaways we execution cap case recently, in marks This remarks the company biotech

dose the for in the half XXXX new limiting of go-forward already important second study, dose in has to by released our presentation escalation early set now escalation successfully in a we This established We dose complete efficacy expect toxicity to trial. have XXXX data dose. the followed THXXXX, of of that will reached of The which and dose. potentially of be portion end takeaway QX in data is the go-forward addition have our basket the with back to be the established regards

a have marketplace development As and with to you. a summer. of infrastructure organization great forward next Thank across are efficient the franchises, create update look call. With great all endeavors. in succeed business from we a critical our cycle everyone life pipelines difficult this, management we and optimizing our strategic to Have allocation our seeing capital our on an a I to witnessed the to of adjustments commercial day

Operator

Thank disconnect. attending concluded. now presentation and now you may you has for today's conference The

Theratechnologies (THTX) 14 Jul 222022 Q2 Earnings call transcript